{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:23:31Z","timestamp":1648751011138},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13104-015-1088-x","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T17:10:22Z","timestamp":1427994622000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A small-fish model for behavioral-toxicological screening of new antimalarial drugs: a comparison between erythro- and threo-mefloquine"],"prefix":"10.1186","volume":"8","author":[{"given":"Hans","family":"Maaswinkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"1088_CR1","volume-title":"World Malaria Report","author":"WHO","year":"2013","unstructured":"WHO. World Malaria Report. Geneva: World Health Organization Press; 2013."},{"key":"1088_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2875-13-49","volume":"13","author":"GS Dow","year":"2014","unstructured":"Dow GS, McCarthy WF, Reid M, Smith B, Tang D, Shanks GD. A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area. Malar J. 2014;13:49.","journal-title":"Malar J"},{"key":"1088_CR3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1258\/jrsm.100.4.170","volume":"100","author":"AM Croft","year":"2007","unstructured":"Croft AM. A lesson learnt: the rise and fall of Lariam and Halfan. J R Soc Med. 2007;100:170\u20134.","journal-title":"J R Soc Med"},{"key":"1088_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/bmj.313.7056.525","volume":"313","author":"PJ Barrett","year":"1996","unstructured":"Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ. 1996;313:525\u20138.","journal-title":"BMJ"},{"key":"1088_CR5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5694\/j.1326-5377.2005.tb06647.x","volume":"182","author":"SJ Kitchener","year":"2005","unstructured":"Kitchener SJ, Nasveld PE, Gregory RM, Edstein MD. Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust. 2005;182:168\u201371.","journal-title":"Med J Aust"},{"key":"1088_CR6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.amepre.2007.04.029","volume":"33","author":"C Korhonen","year":"2007","unstructured":"Korhonen C, Peterson K, Bruder C, Jung P. Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers. Am J Prev Med. 2007;33:194\u20139.","journal-title":"Am J Prev Med"},{"key":"1088_CR7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2310\/7060.2000.00026","volume":"7","author":"E Petersen","year":"2000","unstructured":"Petersen E, Ronne T, Ronn A, Bygbjerg I, Larsen SO. Reported side effects of chloquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med. 2000;7:79\u201384.","journal-title":"J Travel Med"},{"key":"1088_CR8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2165\/00002018-199512060-00003","volume":"12","author":"PA Philips-Howard","year":"1995","unstructured":"Philips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf. 1995;12:370\u201383.","journal-title":"Drug Saf"},{"key":"1088_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4269\/ajtmh.1991.45.86","volume":"45","author":"T Weinke","year":"1991","unstructured":"Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg. 1991;45:86\u201391.","journal-title":"Am J Trop Med Hyg"},{"key":"1088_CR10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/AAC.50.3.1045-1053.2006","volume":"50","author":"G Dow","year":"2006","unstructured":"Dow G, Bauman R, Caridha D, Cabezas M, Du F, Gomez-Lobo R, et al. Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agents Chemother. 2006;50:1045\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR11","first-page":"191","volume":"19","author":"TA Essen van","year":"2010","unstructured":"van Essen TA, van der Giessen RS, Koekkoek SK, Vanderwerf F, Zeeuw CI, van Genderen PJ, et al. Anti-malaria drug mefloquine induces motor learning deficits in humans. Front Neurosci. 2010;19:191.","journal-title":"Front Neurosci"},{"key":"1088_CR12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0001-706X(01)00210-8","volume":"81","author":"P Rendi-Wagner","year":"2002","unstructured":"Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 2002;81:167\u201373.","journal-title":"Acta Trop"},{"key":"1088_CR13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2875-2-14","volume":"2","author":"GS Dow","year":"2003","unstructured":"Dow GS, Hudson TH, Vahey M, Koenig ML. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J. 2003;2:14.","journal-title":"Malar J"},{"key":"1088_CR14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/AAC.00874-07","volume":"52","author":"D Caridha","year":"2008","unstructured":"Caridha D, Yourick D, Cabezas M, Wolf L, Hudson TH, Dow GS. Mefloquine disruption of calcium homeostasis in mammalian cells is similar to that induced in ionomycin. Antimicrob Agents Chemother. 2008;52:684\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.neuro.2010.05.005","volume":"31","author":"JE Hood","year":"2010","unstructured":"Hood JE, Jenkins JW, Milatovic D, Rongzhu L, Aschner M. Mefloquine induces oxidative stress and neurodegeneration in primary rat cortical neurons. Neurotoxicology. 2010;31:518\u201323.","journal-title":"Neurotoxicology"},{"key":"1088_CR16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neuro.2011.01.001","volume":"32","author":"D Milatovic","year":"2011","unstructured":"Milatovic D, Jenkins JW, Hood JE, Yu Y, Rongzhu L, Aschner M. Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase. Neurotoxicology. 2011;32:578\u201385.","journal-title":"Neurotoxicology"},{"key":"1088_CR17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bmcl.2010.01.001","volume":"20","author":"E Milner","year":"2010","unstructured":"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, et al. Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of plasmodium falciparum. Med Chem Lett. 2010;20:1347\u201351.","journal-title":"Med Chem Lett"},{"key":"1088_CR18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13318-011-0047-8","volume":"36","author":"E Milner","year":"2011","unstructured":"Milner E, Sousa J, Pybus B, Melendez V, Gardner S, Grauer K, et al. Characterization of in vivo metabolites of WR319691, a novel compound with activity against plasmodium falsiparum. Eur J Drug Metab Pharmacokinet. 2011;36:151\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1088_CR19","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1039\/b911483a","volume":"7","author":"P Wipf","year":"2009","unstructured":"Wipf P, Mo T, Geib SJ, Caridha D, Dow GS, Gerena L, et al. Synthesis and biological evaluation of the first pentafluorosulfanyl analogs of mefloquine. Org Biomol Chem. 2009;7:4163\u20135.","journal-title":"Org Biomol Chem"},{"key":"1088_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/15419061003642618","volume":"16","author":"R Iglesias","year":"2009","unstructured":"Iglesias R, Spray DC, Scemes E. Mefloquine blockade of pannexin 1 currents: resolution of a conflict. Cell Commun Adhes. 2009;16:131\u20137.","journal-title":"Cell Commun Adhes"},{"key":"1088_CR21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.physbeh.2007.01.023","volume":"91","author":"L Zhu","year":"2007","unstructured":"Zhu L, Weng W. Catadioptric stereo-vision system for the real-time monitoring of 3D behavior in aquatic animals. Physiol Behav. 2007;91:106\u201319.","journal-title":"Physiol Behav"},{"key":"1088_CR22","first-page":"e50681","volume":"82","author":"H Maaswinkel","year":"2013","unstructured":"Maaswinkel H, Zhu L, Weng W. Using an automated 3D-tracking system to record individual and shoals of adult zebrafish. J Vis Exp. 2013;82:e50681.","journal-title":"J Vis Exp"},{"key":"1088_CR23","first-page":"41","volume":"55","author":"L Kim","year":"2014","unstructured":"Kim L, He L, Maaswinkel H, Zhu L, Sirotkin H, Weng W. Anxiety, hyperactivity and stereotypy in a zebrafish model of fragile X syndrome and autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2014;55:41\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1088_CR24","doi-asserted-by":"crossref","first-page":"e51767","DOI":"10.1371\/journal.pone.0051767","volume":"7","author":"N Prochnow","year":"2012","unstructured":"Prochnow N, Abdulazim A, Kurtenbach S, Wildf\u00f6rster V, Dvoriantchikova G, Hanske J, et al. Pannexin1 stabilizes synaptic plasticity and is needed for learning. PLoS One. 2012;7:e51767.","journal-title":"PLoS One"},{"key":"1088_CR25","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.bmcl.2008.03.075","volume":"18","author":"RJ Gillespie","year":"2008","unstructured":"Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, et al. Antagonists of the human adenosine A2A receptor. Part 1: discovery and syntheis of thieno [3,2-d] pyrimidine-4-methanone derivatives. Bioorganic Med Chem Letters. 2008;18:2916\u20139.","journal-title":"Bioorganic Med Chem Letters"},{"key":"1088_CR26","first-page":"B1","volume":"6664397","author":"A Fletcher","year":"2003","unstructured":"Fletcher A, Shepherd R. Administering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (\u2212)-enantiomer; reduced side effects. US Patent. 2003;6664397:B1.","journal-title":"US Patent"},{"key":"1088_CR27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/expr.1993.1042","volume":"76","author":"JM Karle","year":"1993","unstructured":"Karle JM, Olmeda R, Gerena L, Milhous WK. Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol. 1993;76:345\u201351.","journal-title":"Exp Parasitol"},{"key":"1088_CR28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/ml500015r","volume":"5","author":"MJ Chaparro","year":"2014","unstructured":"Chaparro MJ, Vidal J, Angulo-Barturen I, Bueno JM, Burrows J, Cammack N, et al. Case study of small molecules as antimalarials: 2-amino-1-phenylethanol (APE) derivatives. ACS Med Chem Lett. 2014;5:657\u201361.","journal-title":"ACS Med Chem Lett"},{"key":"1088_CR29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2125.1992.tb04081.x","volume":"33","author":"LK Basco","year":"1992","unstructured":"Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against plasmodium falciparum. Br J Clin Pharmacol. 1992;33:517\u201320.","journal-title":"Br J Clin Pharmacol"},{"key":"1088_CR30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0378-4347(00)83840-2","volume":"529","author":"F Gimenez","year":"1990","unstructured":"Gimenez F, Farinotti R, Thuillier A, Hazebroucq G, Wainer IW. Determination of the enantiomers of mefloquine in plasma and whole blood using a coupled achiral-chiral high-performance liquid chromatographic system. J Chromatogr. 1990;529:339\u201346.","journal-title":"J Chromatogr"},{"key":"1088_CR31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.13.6.1011","volume":"13","author":"LH Schmidt","year":"1978","unstructured":"Schmidt LH, Crosby R, Rasco J, Vaughan D. Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine). Antimicrob Agents Chemother. 1978;13:1011\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/jm00248a015","volume":"17","author":"FI Carroll","year":"1974","unstructured":"Carroll FI, Blackwell JT. Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry. J Med Chem. 1974;17:210\u20139.","journal-title":"J Med Chem"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-015-1088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-015-1088-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-015-1088-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T10:45:39Z","timestamp":1598870739000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1756-0500\/8\/122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1186\/s13104-015-1088-x","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]},"article-number":"122"}}